Zobrazeno 1 - 3
of 3
pro vyhledávání: ''
Autor:
Andrew R Clamp, Giovanni Scambia, Jesús García-Donas, Robert W. Holloway, Amit M. Oza, Juliette Meunier, Nicoletta Colombo, Robert L. Coleman, Lara Maloney, Alexandra Leary, Margarita Amenedo Gancedo, Ana Oaknin, David M. O'Malley, Sandra Goble, Josh Bedel, Deborah K. Armstrong, Peter C.C. Fong, Jeffrey C. Goh, Carol Aghajanian, Domenica Lorusso, Johanne I Weberpals, Elizabeth M. Swisher, Jonathan A. Ledermann, Susana Banerjee, Terri Cameron, Andrew Dean
Publikováno v:
Scientia
Gynecologic oncology
Gynecologic oncology
Pacients d'edat avançada; Càncer d'ovaris; Inhibidor de la PARP Pacientes de edad avanzada; Cáncer de ovarios; Inhibidor de PARP Elderly patients; Ovarian cancer; PARP inhibitor Background In the phase 3 trial ARIEL3, maintenance treatment with th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3d7005aea5c1c77d6850dc9f329a5a6
http://hdl.handle.net/10807/167340
http://hdl.handle.net/10807/167340
Autor:
Giovanni Scambia, Saverio Cinieri, Domenica Lorusso, Gabriella Ferrandina, Nicoletta Colombo, Enrico Breda, Ilaria Sabatucci, Antonella Pietragalla, C. Sonetto, Sandro Pignata, Carmine Conte, Sabrina Chiara Cecere, Antonella Savarese, Davide Lombardi, Pierosandro Tagliaferri, M.T. Lapresa, Roberto Sabbatini, C. Pisano, Giuseppa Maltese
Objective Increased Vascular Endothelial Growth Factor Receptor (VEGF) expression in endometrial cancer (EC) is associated with a poor prognosis. Preliminary clinical data reported Bevacizumab effectiveness in EC both as single agent and in combinati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e20d999e249f0df7acd5cb5fd05bf204
https://hdl.handle.net/10807/231180
https://hdl.handle.net/10807/231180
Autor:
Andrea Rosati, Anna Fagotti, Giovanni Scambia, Eleonora Palluzzi, G. Scaletta, Claudia Marchetti, Antonella Pietragalla, M. Arcieri, R. Ergasti
Objective The role of secondary cytoreductive surgery (SCS) in platinum-sensitive recurrent ovarian cancer (PSROC) is still controversial. We investigated the role of SCS in PSROC patients with BRCA1/2 mutation (BRCAmut) who received platinum-based c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5a6a1c60176d834ead912390c77e490
https://hdl.handle.net/10807/178553
https://hdl.handle.net/10807/178553